Status:
COMPLETED
Is NMES Treatment in Sepsis/ Septic Shock Patients Protective in Development of ICU-AW?
Lead Sponsor:
Ondokuz Mayıs University
Conditions:
Intensive Care Unit Acquired Weakness
Sepsis, Severe
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: Sarcopenia (muscle weakness) characterized by a decrease in muscle mass, strength and performance is a condition that increases with old age. Sarcopenia can be seen in 5-13% of patients ho...
Detailed Description
Background: Sarcopenia (muscle weakness) characterized by a decrease in muscle mass, strength and performance is a condition that increases with old age. Sarcopenia can be seen in 5-13% of patients ho...
Eligibility Criteria
Inclusion
- Being in the Intensive Care Unit
- Over the age of 18
- Diagnosed with sepsis/ septic shock
Exclusion
- Under the age of 18
- Pregnancy
- Having a cardiac pacemaker
- Amputated lower limbs
- Having severe venous insufficiency or major injuries to their lower extremities
- Having neuromuscular disease
- Malignancy
Key Trial Info
Start Date :
October 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT04833621
Start Date
October 23 2018
End Date
October 1 2020
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ondokuz Mayis University Faculty of Medicine
Samsun, Atakum, Turkey (Türkiye), 55200